Titan Medical Inc. (T:TMD)

Business Focus: Advanced Medical Equipment & Technology (NEC)

Get the company report for the most recent outlook updated daily

Apr 22, 2024 07:30 am ET

Titan Provides Update on Planned Merger with Conavi

Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to provide this update on its planned merger with Conavi Medical Inc. (“Conavi”) as previously announced on March 18, 2024 (the “Transaction”). As previously announced, Titan has...

Apr 01, 2024 05:00 pm ET

Titan Settles Contractual Dispute with Contract Manufacturer

Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that it has entered into a settlement agreement with a contract manufacturer (“Contractor”). Titan has reached a settlement agreement in connection with a dispute with the Contractor....

Mar 29, 2024 05:41 pm ET

Titan Medical Reports Fiscal Year 2023 Results

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), today reported financial results for the fiscal year ended December 31, 2023. Recent Activities: On August 14, 2023, the Company announced the appointment of Dr. Daniel...

Mar 20, 2024 07:30 am ET

Titan Announces Q&A Session with Shareholders

Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) announces that management will host a webcast Q&A session on March 27, 2024 at 1:00 p.m. ET in connection with the merger agreement entered into by Titan with Conavi Medical Inc. (“Conavi”), which...

Mar 18, 2024 07:30 am ET

Titan Announces Merger Agreement with Conavi

Titan Medical Inc. (“Titan”) (TSX: TMD; OTC: TMDIF) is pleased to announce that it has entered into a definitive amalgamation agreement (the “Amalgamation Agreement”) dated March 17, 2024 with Conavi Medical Inc. (“Conavi”) to combine the companies...

Mar 04, 2024 07:30 am ET

Titan Medical to Report Year-End 2023 Financial Results on March 29, 2024

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that the Company plans to issue its year-end 2023 financial results after the market closing on March 29, 2024. About Titan Medical Titan Medical Inc. (TSX:...

Dec 01, 2023 05:00 pm ET

Titan Medical Announces Benchmark Electronics, Inc. Purported to Terminate Agreement

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today that Benchmark Electronics, Inc., the company engaged by Titan under a manufacturing and supply agreement for the manufacture of Titan’s Enos Surgical System, has...

Nov 02, 2023 07:30 am ET

Titan Medical Reports Operating and Financial Results for the Third Quarter 2023

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today financial results for the three and nine months ended September 30, 2023. Recent Activities: On August 14, 2023, the Company announced the appointment of Dr....

Oct 18, 2023 11:35 am ET

Titan Medical Announces Change in Auditor

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), a medical technology company, announces that it has changed its auditor from BDO Canada LLP (the “Former Auditor”) to MNP LLP (the “Successor Auditor”) effective October 10,...

Aug 21, 2023 07:30 am ET

Titan Medical Signs License Agreement with Auris Health, Inc.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), a medical technology company, announced today that the Company has entered into a licensing agreement (“Agreement”) with Auris Health, Inc., (“Auris Health”), a Johnson & Johnson...

Aug 14, 2023 07:30 am ET

Titan Medical Announces Appointment of New Independent Member to its Board of Directors

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today the appointment of Dr. Daniel O’Brien, MD, MBA, PhD to its Board of Directors. Dr. O’Brien will also serve on the Audit Committee of the Board. “We are pleased...

Aug 10, 2023 05:00 pm ET

Titan Medical Reports Operating and Financial Results for the Second Quarter 2023

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today financial results for the three and six months ended June 30, 2023. Recent Activities: On May 26th and June 5th, respectively, the Company announced IP...

Jul 04, 2023 07:30 am ET

Titan Medical Reports Voting Results From Annual General Meeting of Shareholders

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), a medical technology company, today announced the voting results from the Company’s Annual General Meeting of its shareholders held on June 30, 2023. All of management’s...

Jun 20, 2023 07:30 am ET

Titan Medical Successfully Transitions to an IP Licensing Company

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) is pleased to provide this further corporate update on its successful transition to an IP licensing company. Given the state of the capital markets such that emerging tech...

Jun 16, 2023 07:30 am ET

Titan Medical Announces Lifting of Management Cease Trade Order

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), reports that the management cease trade order granted on April 3, 2023 (the “MCTO”) by the Ontario Securities Commission under National Policy 12-203 – Management Cease Trade...

Jun 09, 2023 05:00 pm ET

Titan Medical Reports Operating and Financial Results for the First Quarter 2023

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today financial results for the three months ended March 31, 2023. Recent Activities: On May 26th and June 5th, respectively, the Company announced IP licensing...

Jun 05, 2023 01:37 pm ET

IIROC Trade Resumption - TMD

TORONTO, June 5, 2023 /CNW/ - Trading resumes in:

Jun 05, 2023 01:30 pm ET

Canadian Investment Regulatory Organization Trading Halt - TMD

TORONTO, June 5, 2023 /CNW/ - The following issues have been halted by CIRO:

Jun 05, 2023 01:30 pm ET

Titan Medical Signs Asset Purchase and License Agreement with Medtronic

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), a medical technology company headquartered in Toronto, Ontario, announced today that the Company has entered into an asset purchase and license agreement (“Agreement”) with...

May 31, 2023 07:54 pm ET

Titan Medical Reports Operating and Financial Results for the Fourth Quarter and Year End 2022 and Announces Availability of Materials for the 2023 Annual Meeting of Shareholders

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF), announced today the financial results for the three and twelve months ended December 31, 2022. The Company also announced that its 2023 annual meeting (the “Meeting”) is...

May 29, 2023 07:30 am ET

Titan Medical Announces Corporate Update and Provides Bi-Weekly MCTO Status Update

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) announced today a corporate update and is also providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 –...

May 26, 2023 02:42 pm ET

IIROC Trade Resumption - TMD

TORONTO, May 26, 2023 /CNW/ - Trading resumes in:

May 26, 2023 02:30 pm ET

Titan Medical Signs License Agreement with Intuitive Surgical

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) announced today that the Company has entered into a license agreement (“Agreement”) with Intuitive Surgical, Inc. (“Intuitive”) (Nasdaq: ISRG), a global technology leader in...

May 26, 2023 02:16 pm ET

IIROC Trading Halt - TMD

TORONTO, May 26, 2023 /CNW/ - The following issues have been halted by IIROC:

May 19, 2023 04:30 pm ET

Titan Medical Announces Delay in First Quarter 2023 Filings

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today announces that, as a result of a delay in filing its annual financial statements, the related management’s discussion and analysis and annual information form, and the...

May 15, 2023 04:30 pm ET

Titan Medical Provides Bi-Weekly MCTO Status Update

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”). On...

May 01, 2023 07:30 am ET

Titan Medical Provides Bi-Weekly MCTO Status Update

Apr 17, 2023 07:30 am ET

Titan Medical Provides Bi-Weekly MCTO Status Update

Apr 04, 2023 07:30 am ET

Titan Medical Announces Receipt of MCTO

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) announces that it has been granted a management cease trade order (“MCTO”) by the Ontario Securities Commission (the “OSC”), as its principal regulator, under National Policy...

Apr 03, 2023 08:39 am ET

Titan Medical Provides Corporate Update

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today provided an update on its annual filings and certain other corporate and operational matters. On March 22, 2023, the Company announced that it would not be filing its...

Mar 22, 2023 05:01 pm ET

Titan Medical Announces Delays in its Annual Filings and Planned Deregistration with the SEC

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD; OTC: TMDIF) today announces that, as a result of certain financial and operational challenges that the Company has experienced over the past several months and as a result of the Company...

Mar 09, 2023 07:30 am ET

Titan Medical Announces Decision of Nasdaq Hearings Panel to Delist Common Shares

Titan Medical Inc. (the “Company” or “Titan”) (Nasdaq: TMDI; TSX: TMD) today announced that it has received a decision of the Nasdaq Hearings Panel (the “Panel”) advising the Company that effective at the open of business on March 10, 2023, the...

Feb 14, 2023 07:30 am ET

Titan Medical Announces Executive Leadership Updates and Receipt of Nasdaq Notification Regarding Audit Committee Requirements

Titan Medical Inc. (the “Company” or “Titan”) (Nasdaq: TMDI; TSX: TMD) today announced senior leadership changes and the receipt of a notification from the Nasdaq Stock Market LLC Listing Qualifications Department stating that following the...

Feb 08, 2023 09:34 am ET

IIROC Trading Halt - TMD

TORONTO, Feb. 8, 2023 /CNW/ - The following issues have been halted by IIROC:

Feb 08, 2023 09:15 am ET

Titan Medical Provides Corporate Update

Titan Medical Inc. (the “Company” or “Titan”) (Nasdaq: TMDI; TSX: TMD) today provided an update on the previously announced review and evaluation of strategic alternatives. As previously disclosed on November 30, 2022, Titan’s Board of Directors...

Feb 08, 2023 08:58 am ET

IIROC Trade Resumption - TMD

TORONTO, Feb. 8, 2023 /CNW/ - Trading resumes in:

Jan 09, 2023 07:30 am ET

Titan Medical Shares Latest Technology Innovation and Announces Meeting Participation During J.P. Morgan Healthcare Conference Week

Dec 28, 2022 05:01 pm ET

Titan Medical Announces Receipt of Nasdaq Listing Determination; Company to Request Hearing

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) (the “Company”), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that, on...

Dec 13, 2022 07:30 am ET

Titan Medical Granted Patent Covering User Experience, Further Enhancing its Intellectual Property in Robotic Assisted Surgery

Dec 07, 2022 07:30 am ET

Titan Medical Suspends Special Meeting of Shareholders in Conjunction with Initiation of Strategic Review Process

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that in view of the commencement of the strategic review process announced on November 30, 2022, the...

Dec 06, 2022 09:10 am ET

Titan Medical Implements Cost-Cutting Measures to Support Strategic Review Process

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will implement certain cost-cutting measures with a view to preserving capital to...

Nov 30, 2022 07:30 am ET

Titan Medical Announces Commencement of Strategic Review Process

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD) (“Titan” or the “Company”), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that its Board of Directors (or the “Board”), in consultation with its...

Nov 17, 2022 07:30 am ET

Titan Medical Announces American Association of Gynecologic Laparoscopy Global Congress Participation

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced its attendance at the American Association of Gynecologic Laparoscopy (AAGL) 51st Global Congress on...

Nov 10, 2022 07:30 am ET

Titan Medical Reports Financial Results for the Third Quarter 2022, and Announces Special Shareholder Meeting

Nov 02, 2022 07:30 am ET

Titan Medical to Issue Third Quarter 2022 Financial Results on November 10, 2022

Sep 26, 2022 07:30 am ET

Titan Medical Announces Appointment of Eric Heinz as Vice President, Market and Corporate Development

Sep 22, 2022 04:00 pm ET

Titan Medical Announces Publication of Patent Application Expanding Commitment to Continued Innovation in Single Access Robotic Assisted Surgery

Sep 12, 2022 07:38 am ET

Titan Medical Signs Definitive Agreement with Medtronic

Sep 06, 2022 07:30 am ET

Titan Medical to Present at the H.C. Wainwright Global Investment Conference

Aug 11, 2022 07:30 am ET

Titan Medical Reports Financial Results for the Second Quarter 2022

Jul 25, 2022 07:30 am ET

Titan Medical to Issue Second Quarter 2022 Financial Results on August 11, 2022

Jun 30, 2022 04:01 pm ET

Titan Medical Announces Appointment of Cary G. Vance as President and Chief Executive Officer

Jun 29, 2022 10:31 am ET

Titan Medical Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Jun 28, 2022 07:30 am ET

Titan Medical Provides Update to Enos Project Timeline

Jun 23, 2022 07:30 am ET

Titan Medical to Participate at the Society of Robotic Surgery Annual Meeting

Jun 21, 2022 07:30 am ET

Titan Medical Announces Agreement with Nissha Medical Technologies

Jun 09, 2022 06:57 pm ET

Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders

Jun 06, 2022 07:30 am ET

Titan Medical Appoints Bill Fahey as Vice President, Manufacturing and Operations

Jun 01, 2022 07:30 am ET

Titan Medical Announces Executive Departure

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced, after careful consideration and a review of the company’s future needs, that Perry Genova, Senior Vice President of Research and Product Development, will depart the company effective immediately.

May 18, 2022 07:30 am ET

Titan Medical to Present at the H.C. Wainwright Global Investment Conference

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos™ robotic single access surgical system at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022 at the Fontainebleau Miami Beach Hotel in Miami, Florida.

May 12, 2022 07:30 am ET

Titan Medical Reports Financial Results for the First Quarter 2022

May 06, 2022 01:23 pm ET

Titan Medical Announces Availability of Materials for the 2022 Annual and Special Meeting of Shareholders

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that its 2022 Annual and Special Meeting (“the Meeting”) is scheduled for Wednesday, June 8, 2022 at 4:00 p.m. ET to be held virtually at

May 03, 2022 07:30 am ET

Titan Medical Announces Purchase Order from Medtronic

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced receipt of a $2.6 million purchase order from Medtronic plc (NYSE: MDT), a global leader in healthcare technology.

Apr 28, 2022 07:30 am ET

Titan Medical to Issue First Quarter 2022 Financial Results on May 12, 2022

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its first quarter 2022 financial results prior to market opening on Thursday, May 12, 2022. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights. Speakers will include Paul Cataford, Interim President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer.

Apr 26, 2022 07:30 am ET

Titan Medical to Present at the Bloom Burton & Co. Healthcare Investor Conference

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS) system, today announced the company will present an overview of its Enos™ robotic single access surgical system at the Bloom Burton & Co. Healthcare Investor Conference, taking place May 2-3, 2022 at the Metro Toronto Convention Center.

Mar 24, 2022 07:30 am ET

Titan Medical Reports Operating and Financial Results for the Fourth Quarter and Year End 2021

Mar 14, 2022 07:30 am ET

Titan Medical to Report Year End 2021 Financial Results on March 24, 2022

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced that the company plans to issue its year end 2021 financial results prior to market opening on Thursday, March 24, 2022. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights. Speakers will include Paul Cataford, Interim President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer.

Mar 08, 2022 07:30 am ET

Titan Medical to Present at the Oppenheimer 32nd Annual Healthcare Conference

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on single access robotic-assisted surgery (RAS), today announced the company will present an overview of its Enos™ robotic single access surgical system at Oppenheimer’s 32nd Annual Healthcare Conference, a virtual investor conference taking place March 15-17, 2022.

Feb 07, 2022 07:30 am ET

Titan Medical Expands Patent Portfolio to More Than 200 Patents and Applications and Clarifies Third-Party Licensing Strategy

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of innovative surgical technologies for single access robotic-assisted surgery (RAS), today announced that it has surpassed 200 patents and patent applications. This important milestone demonstrates the company’s commitment to being an innovation leader in single access robotic-assisted surgery. This broad portfolio protects the company’s proprietary technology and supports its mission in driving better patient outcomes and offering cost benefits and improving hospital efficie

Jan 26, 2022 09:56 am ET

Titan Medical Receives Final Milestone Payment and Retires Senior Secured Loan From Medtronic

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the design and development of innovative surgical technologies for robotic single access surgery, announced today that it has received payment from Medtronic plc after successfully achieving the final milestone under the development and license agreement announced on January 4, 2022. In addition, the senior secured loan from Medtronic has been retired.

Jan 11, 2022 07:30 am ET

Titan Medical Selects Benchmark to Manufacture Enos Robotic Single Access Surgical System

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the design and development of innovative surgical technologies for robotic single access surgery, announced today that it has signed a manufacturing and supply agreement with Benchmark Electronics, Inc. (NYSE: BHE) to produce Titan’s innovative Enos™ robotic single access surgical system workstations and patient carts. These Benchmark manufactured solutions will be integrated with Titan’s proprietary patented and patent-pending cameras and multi-articulating instruments planned to be manufactured by Titan at i

Jan 05, 2022 07:30 am ET

Titan Medical to Participate in H.C. Wainwright BioConnect 2022 Virtual Investor Conference

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of innovative single access robotic-assisted surgery systems and technology, announced today it is scheduled to participate at the H.C. Wainwright & Company BioConnect 2022 Conference, a virtual investor conference taking place January 10-13, 2022.

Jan 04, 2022 07:30 am ET

Titan Medical Completes Final Milestone Under Development Agreement with Medtronic

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of innovative single access robotic-assisted surgery systems and technology, announced today that it completed, on schedule, the final milestone under the development and license agreement with Medtronic plc (NYSE: MDT), the world’s leading medical technology company. With the successful completion of the agreement, Titan is scheduled to receive a license payment in exchange for licensing the developed technologies to Medtronic and Medtronic’s secured loan to Titan will be

Dec 30, 2021 04:48 pm ET

Titan Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of an innovative single access robotic-assisted surgery system, today received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. Nasdaq Rule 5550(a)(2) requires the shares to maintain a minimum bid price of US$1.0

Dec 01, 2021 04:43 pm ET

Titan Medical Announces CEO Transition

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of an innovative single access robotic-assisted surgery system, announced that President and Chief Executive Officer David McNally has stepped down as President and CEO, and resigned from the Board of Directors effective today. Paul Cataford, Chair of the Board, has been appointed Interim President and CEO and Anthony J. Giovinazzo will assume the role of Lead Independent Director of the Board. The Board intends to commence a search process in early 2022 to identify a perm

Nov 11, 2021 07:30 am ET

Titan Medical Reports Third Quarter 2021 Financial Results

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical technology company focused on the development and commercialization of its innovative surgical technologies for robotic-assisted surgery that requires a single patient access point, today announced financial results for the three and nine months ended September 30, 2021.

Nov 03, 2021 07:30 am ET

Titan Medical Announces Expansion of Surgeon Advisory Board

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced changes to its Surgeon Advisory Board (SAB) comprised of industry leaders in single access and robotic-assisted surgery. The SAB will work cohesively with management to advance the company’s Enos™ robotic single access surgical system through clinical studies to be performed following the approval of its planned application to the FDA for an investigational device exemption (IDE), and, u

Nov 01, 2021 07:30 am ET

Titan Medical to Report Third Quarter 2021 Financial Results on November 11, 2021

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery today announced that the company plans to issue its third quarter 2021 financial results prior to market opening on Thursday, November 11, 2021. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights. Speakers will include David McNally, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer.

Oct 28, 2021 04:01 pm ET

Encode Ideas, L.P. Announces the Initiation of Research Coverage on Titan Medical, Inc.

Dover, Delaware--(Newsfile Corp. - October 28, 2021) - Encode Ideas, L.P. Initiates Research on Titan Medical, Inc. (NASDAQ: TMDI) (TSX: TMD). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:

Oct 25, 2021 07:30 am ET

Titan Medical Announces Completion of Pre-Clinical GLP Studies

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed its scheduled pre-clinical studies with its Enos™ robotic single access surgical system, performed in accordance with FDA’s good laboratory practice (GLP) regulations. GLP is a set of principles intended to assure the quality and integrity of non-clinical laboratory studies that are intended to support marketing permits for products regulated by government agencies.

Sep 14, 2021 07:30 am ET

Titan Medical to Participate in Upcoming Investor Conferences in September

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system and participate in one-on-one investor meetings at two upcoming investor conferences:

Sep 07, 2021 07:30 am ET

Titan Medical to Participate in H.C. Wainwright Investor Conference

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the development and commercialization of its innovative surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system at the H.C. Wainwright 23rd Annual Global Investment Conference on Monday, September 13, 2021. The presentation will be webcast and available on demand starting at 7:00 a.m. ET. The webcast can be accessed via the Investor Relations section o

Aug 11, 2021 07:30 am ET

Titan Medical Reports Second Quarter 2021 Financial Results

Aug 03, 2021 07:30 am ET

Titan Medical to Report Second Quarter 2021 Financial Results on August 11, 2021

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that the company plans to issue its second quarter 2021 financial results prior to market opening on Wednesday, August 11, 2021. In addition, management will host an investor audio webcast at 8:30 a.m. ET to discuss financial results and business highlights. Speakers will include David McNally, President and Chief Executive Officer, and Stephen Lemieux, Chief Financial Officer.

Aug 02, 2021 07:30 am ET

Titan Medical Announces Appointment of Tammy Carrea as Vice President of Quality and Regulatory Affairs

Jul 22, 2021 07:30 am ET

Titan Medical to Participate in Alliance Global Partners Virtual MedTech Summer Investor Conference

Titan Medical Inc. (Nasdaq:TMDI; TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, and Stephen Lemieux, Chief Financial Officer, will be meeting with investors during the Alliance Global Partners Virtual MedTech Summer Investor Conference on Thursday, July 29, 2021.

Jul 12, 2021 07:30 am ET

Titan Medical Announces Appointment of New Chief Financial Officer

Titan Medical Inc. (Nasdaq:TMDI; TSX:TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the appointment of Stephen Lemieux as the Chief Financial Officer of the Company. Mr. Lemieux has more than 18 years of experience working in Nasdaq and TSX listed companies primarily focused in the health care industry. Mr. Lemieux has been involved with or led numerous debt and equity financings, licensing and M&A transactions valued at over $400 million. Previously, Mr. Lemieux served as Chief Financial O

Jun 10, 2021 07:30 am ET

Titan Medical Reports Voting Results From Annual and Special Meeting of Shareholders

May 28, 2021 07:30 am ET

Titan Medical Receives License Fee of $10 Million Upon Achievement of Milestone Under Medtronic Development Agreement

May 24, 2021 07:30 am ET

Titan Medical Announces Addition of Deepak Basra as Vice President, Strategy and Business Development

May 19, 2021 07:55 am ET

Titan Medical to Present at Oppenheimer MedTech Summit Investor Conference

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President and CEO of Titan Medical, will present an overview of the company and its Enos™ robotic single access surgical system at the Oppenheimer MedTech Summit Investor Conference on Wednesday, May 26, 2021 available at 8:00 a.m. ET. A link to the presentation will be available on Titan Medical’s website under the “Investors” section.

May 17, 2021 07:30 am ET

Titan Medical Reports First Quarter 2021 Financial Results and Provides Board Update

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces financial results for the three months ended March 31, 2021. During the first quarter of 2021 the company raised proceeds of $34.5 million from two equity financings and $10 million from the exercise of warrants issued to investors in previous offerings. Titan also announces changes to its board of directors appointing Paul Cataford as Chairman of the Board and Heather Knight as an independent member of the board. In a

May 04, 2021 07:30 am ET

Titan Medical to Report First Quarter 2021 Financial Results May 17, 2021

Apr 22, 2021 07:30 am ET

Titan Medical Expands Senior Leadership Team

Apr 05, 2021 07:30 am ET

Titan Medical to Present at Bloom Burton & Co. Healthcare Investor Conference

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President, CEO and Chairman of Titan Medical, will present an overview of the Company and its Enos™ robotic single access surgical system at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 21, 2021 at 2:00 p.m. ET. A link to the presentation will be available shortly after the conclusion of the live presentation on Titan Medical’s website u

Mar 10, 2021 06:45 am ET

Titan Medical to Participate in Upcoming Investor Conferences

Mar 09, 2021 06:45 am ET

Titan Medical Issues Corporate Update

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced a corporate update in conjunction with its presentation at the H.C. Wainwright Global Life Sciences Conference. David McNally, President, CEO and Chairman of Titan Medical, will provide an overview of the Company and its Enos™ robotic single access surgical system at the conference, which is available for on-demand access on Titan Medical’s website under the “

Mar 02, 2021 07:00 am ET

Titan Medical to Present at H.C. Wainwright Global Life Sciences Conference

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that David McNally, President, CEO and Chairman of Titan Medical, will present an overview of the Company and its Enos™ robotic single access surgical system at the H.C. Wainwright virtual Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 a.m. ET. A link to the presentation will be available for on-demand access beginning Tuesday, March 9, 2021, on Titan Medical’s websi

Feb 24, 2021 09:22 am ET

Titan Medical Announces Closing of US $23M Bought Deal Offering Including Full Exercise of Over-Allotment Option

Feb 22, 2021 08:56 am ET

Titan Medical Reports Year-End 2020 Financial Results

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced the release of its annual financial results for the years ended December 31, 2020 and 2019. During the year ended December 31, 2020, the Company generated revenue of $20.0 million, resulting from development and license agreements with Medtronic plc, and raised aggregate net proceeds of approximately $22.0 million from equity financings and approximately $2.7 million from the exercise

Feb 19, 2021 08:36 pm ET

Titan Medical Announces Filing of Final Short Form Prospectus

Feb 16, 2021 07:00 am ET

Titan Medical Launches “Titan Living Labs” Showcasing a Behind-the-Scenes Look at Product Development

Feb 09, 2021 10:21 am ET

Titan Medical to Report Year-End 2020 Financial Results and Host Webcast on February 22, 2021

Feb 08, 2021 04:56 pm ET

Titan Medical Announces Filing of Preliminary Short Form Prospectus

Feb 03, 2021 08:09 am ET

Titan Medical Announces Upsize to Previously Announced Bought Deal Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced it has entered into an agreement with Bloom Burton Securities Inc. (the “Underwriter”) to increase the amount of its previously announced “bought deal” offering. The Underwriter has now agreed to purchase, on a “bought deal” basis, 8,335,000 units of the Company (the “Units”) at a price of $2.40 per Unit (the “Offering Price”) for aggregate gros

Feb 02, 2021 04:43 pm ET

Titan Medical Announces Us $15 Million Bought Deal Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced it has entered into an agreement with Bloom Burton Securities Inc. (the “Underwriter”) pursuant to which the Underwriter has agreed to purchase, on a “bought deal” basis, 6,250,000 units of the Company (the “Units”) at a price of $2.40 per Unit (the “Offering Price”) for aggregate gross proceeds of $15,000,000 (the “Offering”).

Jan 26, 2021 09:33 am ET

Titan Medical Announces Closing of US $11.5M Bought Deal Offering Including Full Exercise of Over-Allotment Option

Jan 25, 2021 09:29 am ET

IIROC Trade Resumption - TMD

TORONTO, Jan. 25, 2021 /CNW/ - Trading resumes in:

Jan 25, 2021 09:24 am ET

IIROC Trading Halt - TMD

TORONTO, Jan. 25, 2021 /CNW/ - The following issues have been halted by IIROC:

Jan 21, 2021 07:45 pm ET

Titan Medical Announces Filing of Final Short Form Prospectus

Jan 11, 2021 03:17 pm ET

Titan Medical Announces Filing of Preliminary Short Form Prospectus

Jan 05, 2021 04:24 pm ET

Titan Medical Announces US$10 Million Bought Deal Offering

Dec 30, 2020 07:30 am ET

Titan Medical Provides Regulatory Update

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that the Company has received a written response from the U.S. Food & Drug Administration (“FDA”) to its Request for Information in a

Dec 24, 2020 09:52 am ET

Titan Medical Reports Full Compliance with Nasdaq Listing Criteria

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces that on December 24, 2020, the Company received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that the Comp

Dec 07, 2020 07:00 am ET

Microbix Announces Addition to Board of Directors

Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that Mr. Anthony J. Giovinazzo, an accomplished leader in the international life sciences industry, has joined its Board of Directors....

Dec 03, 2020 07:30 am ET

Titan Medical to Present at the Benzinga Global Small Cap Conference

Nov 16, 2020 07:00 am ET

Titan Medical Reports Third Quarter Financial Results

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces financial results for the three and nine months ended September 30, 2020, highlighted by the Company’s improved cash position, which, as of September 30, 2020, reflects a positive difference of approximately $24 million compared to its cash position at December 31, 2019.

Oct 26, 2020 07:30 am ET

Titan Medical Announces Achievement of $10 Million Technical Milestone Under Medtronic Development and License Agreement

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announced today that it has completed the first technical milestone under the development and license agreement with Medtronic plc (“Medtronic”) (NYSE: MDT), and is due to receive a U.S. $10 million payment.

Oct 07, 2020 08:00 am ET

Titan Medical Announces Election of Three New Independent Members to Its Board of Directors

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of robotic surgical technologies for single access surgery, today announced the election of Paul Cataford, Anthony J. Giovinazzo and Cary G. Vance to its Board of Directors. All three individuals were nominated by the Board and were approved by shareholders voting at the Company’s Annual and Special Meeting of Shareholders on September 30th (the “AGM”). Subsequent to the AGM, the Board held a meeting and the following elections to Board commi

Oct 01, 2020 08:00 am ET

Titan Medical Reports Voting Results from Annual and Special Meeting of Shareholders

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of robotic surgical technologies, announced the voting results from the Company’s Annual and Special Meeting of its Shareholders held on Wednesday, September 30, 2020.

Sep 21, 2020 08:00 am ET

Titan Medical Reveals New Robotic Surgical System Brand Identity and Updated Corporate Brand Identity

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of robotic surgical technologies, announced today the launch of a new name and brand identity for its robotic surgical system under development, the Enos™ robotic single access surgical system.

Sep 17, 2020 08:00 am ET

Titan Medical Announces Intellectual Property Portfolio Expansion with Issuance of Robotic Surgery Patents Related to Camera and System Control

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that it has recently been issued two U.S. patents, increasing its global intellectual property portfolio to 58 issued patents and 84 patent applications. The Company has also received notices of allowance in 17 other patent applications and accordingly anticipates their issuance in the coming months.

Sep 09, 2020 08:00 am ET

Titan Medical Inc. to Present at the H.C. Wainwright Virtual Conference

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, today announced that it is scheduled to present at the H.C. Wainwright Investor Conference on Monday, September 14, 2020 at 2:00 PM ET. David McNally, President and CEO of Titan will be presenting to a live virtual audience available by webcast at

Sep 08, 2020 08:00 am ET

Titan Medical Announces Chief Financial Officer Retirement and Successor Appointment

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, today announced its Chief Financial Officer (CFO) Stephen Randall will retire after more than 10 years with Titan. As part of the Company’s succession planning process, Monique L. Delorme, currently Vice President, Finance at Titan, will be promoted to CFO effective October 1, 2020.

Aug 26, 2020 09:00 am ET

Titan Medical Inc. to Present at the LD 500 Virtual Conference

TORONTO, ON / ACCESSWIRE / August 26, 2020 /Titan Medical Inc. ("Titan" or the "Company") (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, today announced that it is scheduled to present at the LD 500 investor conference on Wednesday, September 2, 2020 at 11:20 AM ET. David McNally, President and CEO of Titan will be presenting to a live virtual audience available by webcast at http://www.webcaster4.com/webcast/page/2019/36162.

Aug 12, 2020 05:30 pm ET

Titan Medical Reports Second Quarter 2020 Financial Results

Aug 10, 2020 08:00 pm ET

Titan Medical Confirms Receipt of Deficiency Notice From Nasdaq

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, today announced that on August 5, 2020, the Company received a deficiency notice from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares (the “Shares”) listed on Nasdaq was below US$1.00 for 30 consecutive business days.

Jul 30, 2020 08:00 am ET

Titan Medical Reports Design Enhancements to Single-Port Robotic Surgical Instruments on Product Development Resumption

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that it has completed design enhancements to instruments compatible for use with its single-port robotic surgical system. As previously disclosed, the Company resumed development of instruments for its single-port robotic surgical system in June 2020 following the completion of a financing for gross proceeds of US$18 million.

Jul 27, 2020 08:00 am ET

Titan Medical to Present at the Society of Robotic Surgery 2020 World Robotic Symposium

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that David McNally, President and CEO of Titan Medical, will present in the plenary session titled “Future Robotic Platforms” on Saturday, August 1 at the Society of Robotic Surgery (SRS) 2020 World Robotic Symposium. This industry-focused plenary session will feature executives from companies recognized for current and promising technology platforms in robotic surgery.

Jul 14, 2020 08:00 am ET

Titan Medical Issues Shareholder Update Letter

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, today issued an update letter to its shareholders. The letter, authored by David McNally, President & CEO, Chairman, may be found on the Company’s website and a full text of the letter follows.

Jun 25, 2020 08:00 am ET

Titan Medical Promotes Globally Recognized Intellectual Property Strategy Leader to Vice President and General Counsel

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that its head of intellectual property, Jasminder Brar, has been promoted to Vice President of Legal, IP and Strategic Initiatives, and General Counsel. Mr. Brar has lead Titan’s strategic IP efforts since 2011 and is recognized as a global IP strategy leader, having been named to the IAM Strategy 300: The World’s Leading IP Strategists since 2015. In this expanded role, Mr. Brar will also s

Jun 22, 2020 08:00 am ET

Titan Medical Reports Full Compliance with Nasdaq Listing Criteria

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that on June 18, 2020, The Nasdaq Stock Market LLC (“Nasdaq”) staff determined that the Company has cured the Market Value of Listed Securities and bid price deficiencies and has regained full compliance with all applicable criteria for continued listing and trading on The Nasdaq Capital Market. Accordingly, the Nasdaq Hearings Panel scheduled for July 16, 2020 has been cancelled.

Jun 16, 2020 11:02 am ET

IIROC Trading Halt - TMD

TORONTO, June 16, 2020 /CNW/ - The following issues have been halted by IIROC:

Jun 16, 2020 10:37 am ET

IIROC Trade Resumption - TMD

TORONTO, June 16, 2020 /CNW/ - Trading resumes in:

Jun 15, 2020 08:00 am ET

Titan Medical Establishes U.S. Subsidiary to Strengthen its Research and Product Development Activities

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that it has established Titan Medical USA Inc. as a wholly owned U.S. subsidiary. The subsidiary will be based in Chapel Hill, North Carolina at a facility that will initially be used for research and development activities. The facility includes a custom buildout, the costs for which are included in monthly lease payments.

Jun 11, 2020 02:24 pm ET

Titan Medical Announces Closing of US$18.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, is pleased to announce today that it closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 18,000,000 common shares of the Company (the “Common Shares”) or Common Shares equivalents at a price of US$1.00 per Common Share or Common Share equivalent and 9,000,000 Common Share purchase warrants (each, a “

Jun 11, 2020 07:30 am ET

Titan Medical Appoints Phillip L. McStotts, CPA, CGMA to Board of Directors

Mr. McStotts is a successful entrepreneur with 30 years of experience in the medical device industry, having been a Chief Financial Officer in both public and private companies. He has co-founded start-up companies that have commercialized best-in-class surgical, life and organ support, diagnostic and home-care capital equipment and disposables. He has raised investment capital from institutional and retail investors, angel investors, venture capital, private equity, strategic partners, and a healthcare royalty fund. Mr. McStotts negotiated a reverse-merger into a public company and thereafter

Jun 10, 2020 10:20 am ET

IIROC Trade Resumption - TMD

TORONTO, June 10, 2020 /CNW/ - Trading resumes in:

Jun 10, 2020 10:15 am ET

IIROC Trading Halt - TMD

TORONTO, June 10, 2020 /CNW/ - The following issues have been halted by IIROC:

Jun 09, 2020 02:22 pm ET

IIROC Trade Resumption - TMD

TORONTO, June 9, 2020 /CNW/ - Trading resumes in:

Jun 09, 2020 02:18 pm ET

IIROC Trading Halt - TMD

TORONTO, June 9, 2020 /CNW/ - The following issues have been halted by IIROC:

Jun 09, 2020 12:42 pm ET

IIROC Trade Resumption - TMD

TORONTO, June 9, 2020 /CNW/ - Trading resumes in:

Jun 09, 2020 12:37 pm ET

IIROC Trading Halt - TMD

TORONTO, June 9, 2020 /CNW/ - The following issues have been halted by IIROC:

Jun 09, 2020 08:00 am ET

Titan Medical Announces Settlement of Pending Litigation With Naglreiter Consulting, LLC

Titan Medical Inc. (“Titan” or “Titan Medical”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that it has entered into a settlement agreement with Naglreiter Consulting, LLC, d/b/a Naglreiter MDDO (“Naglreiter”) to settle claims in the lawsuit styled Naglreiter Consulting LLC, d/b/a Naglreiter MDDO v. Titan Medical Inc. (Case No. 0:19-cv-62574) pending in the United States District Court for the Southern District of Florida.

Jun 08, 2020 09:24 am ET

Titan Medical Announces US$18.0 Million Registered Direct Offering Priced At-the-Market

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has entered into definitive agreements with a single healthcare-focused institutional investor that provide for the purchase and sale of 18,000,000 common shares of the Company (the “Common Shares”) (or Common Shares equivalents) at a per share purchase price of US$1.00 per Co

Jun 04, 2020 07:30 am ET

Titan Medical Announces Development and License Agreements With Medtronic and Senior Secured Loan

Titan Medical Inc. (“Titan” or “Titan Medical”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that it has entered into a development and license agreement with Medtronic plc (“Medtronic”) (NYSE: MDT) to further the development of robotic assisted surgical technologies, as well as a separate license agreement with Medtronic in respect of certain intellectual property of Titan.

May 27, 2020 08:00 am ET

Titan Medical Receives Nasdaq Delisting Notification and Discloses Plans for Appeal

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that on May 26, 2020 it received a Staff Delisting Determination letter (the “Determination”) from The Nasdaq Stock Market, LLC setting forth a determination to delist the Company's common shares from The Nasdaq Capital Market as a result of the Company's failure to comply with the Listing Rule 5550(b) which requires a minimum of $2.5 million in stockh

May 13, 2020 04:30 pm ET

Titan Medical Reports First Quarter 2020 Financial Results

May 06, 2020 09:29 am ET

Titan Medical Announces Closing of US$2.0 Million Registered Direct Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 5,514,504 common shares of the Company (the “Common Shares”) at a price of US$0.36268 per Common Share and 2,757,252 unregistered Common Share purchase warr

May 04, 2020 09:00 am ET

Titan Medical Announces US$2.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has entered into definitive agreements with institutional investors that provide for the purchase and sale of 5,514,504 common shares of the Company (the “Common Shares”) at a per share purchase price of US$0.36268 per Common Share in a registered direct offering priced at-the

Apr 30, 2020 08:00 am ET

Titan Medical and Its Primary Product Development Supplier Agree to Payment Plan for Outstanding Amounts and Resumption of Development Services

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has entered into a letter agreement (“Letter Agreement”) with its primary product development supplier (“Primary Supplier”) for the payment of outstanding payables.

Apr 29, 2020 08:50 am ET

Titan Medical Announces $1.5 Million Senior Secured Loan Facility With a Leading Global Medical Technology Company

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has closed a US$1.5 million senior secured loan facility (“Loan Facility”) from a leading global medical technology company. The Loan Facility has an interest rate of 8% per annum and is repayable not later than April 29, 2023.

Mar 30, 2020 09:33 pm ET

Titan Medical Reports 2019 Financial Results

Titan Medical Inc. (“Titan” or “the Company”) (TSX: TMD) (NASDAQ: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the twelve months ended December 31, 2019.

Mar 27, 2020 11:37 am ET

Titan Medical Announces Closing of US$1.2 Million Registered Direct Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it closed its previously announced registered direct offering for the purchase and sale of 7,000,000 common shares of the Company (the “Common Shares”) at a purchase price of US$0.17 per Common Share and 3,500,000 Common Share purchase warrants (each, a “Warrant”), resulting in t

Mar 26, 2020 08:16 am ET

Titan Medical Expands and Strengthens Global Intellectual Property Portfolio With Issuance of Robotic Surgery Patents

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that its global intellectual property portfolio has increased to 49 issued patents and 86 patent applications, including the recent granting and filing of patent applications directed at innovative robotic surgery technologies.

Mar 25, 2020 08:58 am ET

Titan Medical Announces US$1.2 Million Registered Direct Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has entered into definitive agreements with institutional investors that provide for the purchase and sale of 7,000,000 common shares of the Company (the “Common Shares”) at a per share purchase price of $0.17 per Common Share and 3,500,000 Common Share purchase warrants (each

Feb 11, 2020 08:12 am ET

Titan Medical Announces Departure of Director Domenic Serafino

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces that Domenic (Dom) Serafino has resigned as a Director of the Company. Titan has begun the process of seeking qualified candidates to fill this vacancy.

Feb 03, 2020 08:26 am ET

Titan Medical Issues Letter to Shareholders

Jan 27, 2020 08:28 am ET

Titan Medical Receives ISO 13485 Certification, Provides Update on Fourth Quarter Milestones

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), today announced receipt of ISO 13485 Certification from a European Notified Body following completion of audits of the Company’s quality system and related documentation. This certification represents that Titan’s quality management system (“QMS”) maintains standards that meet international requirements specific to medical device design and development.

Jan 06, 2020 07:30 am ET

Titan Medical and Cambridge Design Partnership Announce Expanded Engagement for Robotic Instrument Development

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), and Cambridge Design Partnership Ltd. (“CDP”), a leading patient-centric product and technology innovation company specializing in the healthcare sector, today announce an expanded engagement in respect of the instrument development program for Titan’s single-port robotic surgical system. Additionally, CDP has subscribed for common shares of Titan.

Dec 23, 2019 09:17 am ET

Titan Medical Announces New Common Share Purchase Agreement With Aspire Capital Fund of up to US$35 Million

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has entered into a Common Share Purchase Agreement (the “Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”) where Aspire Capital has committed to purchase up to US$35.0 million of common shares of Titan at Titan’s request from time to time, until June 23, 2022. This new Agreement replaces the prior Common Share Purchase Agre

Dec 04, 2019 05:00 pm ET

Titan Medical Confirms Receipt of Deficiency Notices From Nasdaq

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), today announced that on November 27, 2019, the Company received notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the Company's common shares (the “Shares”) listed on Nasdaq was below

Nov 21, 2019 08:29 am ET

Titan Medical to Participate in Two Investment Conferences in December

Nov 14, 2019 05:39 pm ET

Titan Medical Reports Third Quarter 2019 Financial Results

Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or “the Company”), a medical device company focused on the design and development of a single-port robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the three and nine months ended September 30, 2019.

Nov 07, 2019 08:37 am ET

Titan Medical Determines Not to Proceed with Public Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has determined not to proceed with the public offering of units of the Company for which it filed a final short form prospectus on October 31, 2019. The Company has made this decision based on its assessment of market conditions, and intends to pursue alternative financing options.

Nov 01, 2019 03:29 pm ET

Titan Medical Announces Filing of Final Prospectus

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has filed and been receipted for a final short form prospectus (the “Final Prospectus”) in connection with the previously announced marketed offering (the “Offering”) of units of the Company (the “Units”) at a price of US $0.45 per Unit for minimum gross proceeds of US $15,000

Oct 25, 2019 09:39 am ET

IIROC Trade Resumption - TMD

TORONTO, Oct. 25, 2019 /CNW/ - Trading resumes in:

Oct 25, 2019 09:32 am ET

Titan Medical Announces Pricing of Marketed Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has priced its previously announced marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offering, Titan will issue Units at a price of US $0.45 per Unit for total gross proceeds of a minimum of US $15,000,000 and a maximum of US $25

Oct 25, 2019 09:00 am ET

IIROC Trading Halt - TMD

TORONTO, Oct. 25, 2019 /CNW/ - The following issues have been halted by IIROC:

Oct 15, 2019 05:31 pm ET

Titan Medical Announces Filing of Amended and Restated Preliminary Prospectus and Withdrawal of Previously Published Milestones

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has filed and been receipted for an amended and restated preliminary short form prospectus (the “A&R Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan has also filed a corresponding registration statement on Form F-1

Oct 01, 2019 08:50 am ET

Titan Medical Continues to Market Offering of Units

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced on Monday, September 23, 2019 that it had filed and been receipted for a preliminary short form prospectus (the “Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan had also filed a corresponding registration statement on Form F-10 (the “

Sep 25, 2019 07:59 am ET

IIROC Trade Resumption - TMD

TORONTO, Sept. 25, 2019 /CNW/ - Trading resumes in:

Sep 24, 2019 05:00 pm ET

Titan Medical Continues to Market Offering of Units

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced Monday, September 23, 2019 that it had filed and been receipted for a preliminary short form prospectus (the “Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan had also filed a corresponding registration statement on Form F-10 (the “R

Sep 23, 2019 04:59 pm ET

IIROC Trading Halt - TMD

TORONTO, Sept. 23, 2019 /CNW/ - The following issues have been halted by IIROC:

Sep 23, 2019 04:39 pm ET

Titan Medical Announces Overnight Marketed Offering of Units

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has filed and been receipted for a preliminary short form prospectus (the “Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan has also filed a corresponding registration statement on Form F-10 (the “Registration Statement

Sep 06, 2019 09:05 am ET

Titan Medical Announces Change to Presentation Time at H.C. Wainwright Conference

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that management’s presentation at the H.C. Wainwright 21st Annual Global Investment Conference has been moved to 2:35 p.m. Eastern time on Tuesday, September 10. The presentation had previously been scheduled for 4:15 p.m. Eastern time that day. Management’s presentation will be webcast live and a replay will be available on the Investor Rela

Sep 03, 2019 04:26 pm ET

Titan Medical to Webcast Wells Fargo Healthcare Conference Presentation

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that owing to a change in format, management will deliver a corporate presentation at the 2019 Wells Fargo Healthcare Conference at 3:35 p.m. Eastern time on September 4th. The presentation will be webcast live and a replay will be available on the Investor Relations portion of the Company’s website.

Sep 03, 2019 08:54 am ET

Titan Medical Strengthens Robotic Surgery U.S. Patent Portfolio With Grant for Surgical Imaging Technology

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery, announces that it has been granted U.S. Patent No. 10,398,287, titled “Camera Positioning System, Method, and Apparatus for Capturing Images During a Medical Procedure.” The patent is directed at aspects of the Company’s innovative dual-view camera system for use in robotic surgery, including single-port robotic surgery.

Aug 29, 2019 05:25 pm ET

Titan Medical Announces Common Share Purchase Agreement With Aspire Capital Fund of up to US$35 Million

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that it has entered into a Common Share Purchase Agreement (the “Agreement”) with Aspire Capital Fund, LLC (“Aspire Capital”) where Aspire Capital has committed to purchase up to US$35.0 million of common shares of Titan at Titan’s request from time to time, until February 28, 2022. On commencement of the Agreement, Titan will immediately sel

Aug 27, 2019 08:28 am ET

Titan Medical to Present at Upcoming September Investment Conferences

Aug 26, 2019 08:45 am ET

Titan Medical Announces Successful Completion of Human Factors Evaluation for Its Single-Port Robotic Surgical System, Provides Development and Regulatory Update

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that the human factors evaluation (“HFE”) required to support its planned Investigational Device Exemption (“IDE”) filing with the U.S. Food and Drug Administration (“FDA”) was completed successfully and received a highly favorable assessment from the surgeon investigators.

Aug 06, 2019 08:50 am ET

Titan Medical Announces Successful Completion of Survival Phase of GLP Chronic Procedures with its Single-Port Robotic Surgical System

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces the successful completion of the chronic procedures performed under Good Laboratory Practice (“GLP”) principles using its single-port robotic surgery system, noting that all animals survived through the follow-up period. Ricardo Estape, M.D., a robotic gynecologic oncology surgeon specializing in robotic single incision surgeries from South M

Jul 31, 2019 05:57 pm ET

Titan Medical Reports Second Quarter 2019 Financial Results

Titan Medical Inc. (TSX: TMD) (NASDAQ: TMDI) (“Titan” or “the Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces financial results for the three and six months ended June 30, 2019.

Jul 23, 2019 08:39 am ET

Titan Medical a Letter to the Shareholders from the President and CEO

Dear Titan Medical Shareholders,

Jul 18, 2019 08:43 am ET

Titan Medical Completes Preclinical Good Laboratory Practice Procedures With Its Single-Port Robotic Surgical System

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that all procedures under Good Laboratory Practice (“GLP”) principles associated with the acute and chronic animal studies and human cadaver studies using its single-port robotic surgery system have been completed. The Company intends to announce the results of required follow-up to the chronic procedures by the end of August.

Jul 08, 2019 07:30 am ET

Titan Medical Names Surgical Robotics Sales Veteran Chad A. Zaring as its Chief Commercial Officer

(July 8, 2019) – Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that Chad A. Zaring has joined the Company as chief commercial officer, a new position. Mr. Zaring has deep experience developing and executing commercial strategies and driving sales for leading surgical robotics companies and will be responsible for the launch of Titan’s single-port robotic surgery system following receipt

Jun 13, 2019 08:25 am ET

Titan Medical to Present and Exhibit at the Society of Robotic Surgery 2019 Annual Meeting

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that David McNally, President and CEO of Titan Medical, will present in the plenary session titled “Innovations in Robotic Technologies, What The Future Holds In Store” on Thursday, June 20 at the Society of Robotic Surgery 2019 Annual Meeting in Orlando. This industry-focused plenary session w

May 31, 2019 08:57 am ET

Titan Medical Inc. Announces Voting Results from Its Annual and Special Meeting of Shareholders

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery, reported shareholder vote results from the Company’s Annual and Special Meeting held on Wednesday, May 29, 2019.

May 22, 2019 05:15 pm ET

Titan Medical Annual and Special Meeting Scheduled for Wednesday, May 29, 2019

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces that its 2019 Annual and Special Meeting is scheduled for Wednesday, May 29, 2019 at 12:00 p.m. (Eastern), to be held at the Toronto Hilton Hotel, 145 Richmond Street West, Simcoe Room, Main Lobby.

May 14, 2019 06:56 pm ET

Titan Medical Reports First Quarter 2019 Financial Results

May 01, 2019 07:00 am ET

Titan Medical Names Prominent Medical Technology Executive Charles Federico as Chairman of the Board

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces the appointment of Charles W. Federico, age 70, as Chairman of the Company’s Board of Directors, effective immediately. Mr. Federico is assuming the Board seat held by Bruce Wolff, M.D. who has resigned from the Board and is being retained as a Senior Advisor to the Company. Current

Apr 30, 2019 07:00 am ET

Titan Medical Announces Hardware Design Freeze for its Single-port Robotic Surgery System

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), announces it has achieved hardware design freeze for its single-port robotic surgery system. This design freeze is the culmination of engineering work based on product feedback gathered from extensive preclinical feasibility studies at three Centers of Excellence and ongoing Formative Human

Apr 23, 2019 07:00 am ET

Titan Medical to Present at the Bloom Burton & Co. Healthcare Investor Conference

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in single-port minimally invasive surgery (“MIS”), today announced that David McNally, President and CEO of the Company, will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 30 at 1:30 p.m. Eastern time. The conference will be held April 30-May 1 at the Metro Toronto Convention Ce

Mar 25, 2019 07:00 am ET

Titan Medical and Teleflex Incorporated Announce Collaboration for Development of Robotic Ligation Technology

Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”) and Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care and surgery, announce a collaboration under which Teleflex’s market-leading polymer ligation technology will be integrated into Titan’s development-stage, single-port robotic surgery system. Teleflex’s Weck®

Mar 22, 2019 07:30 am ET

Titan Medical to Webcast Business Update Conference Call on March 28, 2019

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that management will webcast a conference call on Thursday, March 28 at 4:30 p.m. ET to provide a business update on the Company and its SPORT Surgical System. Speakers on the call will include David J. McNally, Chief Executive Officer of Titan Medical and Stephen D. R

Mar 21, 2019 04:30 pm ET

Titan Medical Closes Public Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce the closing of its previously announced public offering (the “Offering”) pursuant to an agency agreement dated March 18, 2019 between the Company and Bloom Burton Securities Inc. (the “Agent”).

Mar 19, 2019 07:00 am ET

Titan Medical Announces Filing of Final Prospectus

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce that yesterday it filed and was receipted for a final short form prospectus (the “Final Prospectus”) in connection with the previously announced marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offerin

Mar 06, 2019 09:35 am ET

Titan Medical Announces Pricing of Overnight Marketed Offering

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), is pleased to announce today that it has priced its previously announced overnight marketed offering (the “Offering”) of units of the Company (the “Units”). Pursuant to the Offering, Titan will issue Units at a price of US $3.40 per Unit for total gross proceeds of a mini

Mar 05, 2019 04:29 pm ET

Titan Medical Announces Overnight Marketed Offering of Units

Titan Medical Inc. (“Titan” or the “Company”) (TSX:TMD) (NASDAQ:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (“MIS”), announced today that it has filed and been receipted for a preliminary short form prospectus (the “Preliminary Prospectus”) with securities regulators in the provinces of Ontario, British Columbia and Alberta. Titan has also filed a corresponding registration statement on Form F

Feb 27, 2019 09:02 am ET

Titan Medical Expands Global Intellectual Property Portfolio to 30 Patents Issued and 75 Pending with Receipt of First Patent in China

Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (“Titan” or the “Company”), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery (“MIS”), announces that its global intellectual property portfolio has increased to 30 issued patents and 75 pending applications through the recent granting and filing of patent applications directed at aspects of its innovative robotic surgery program. Included in the recent patent grants is the Company’s first patent in C

Ad blocking detected

Titan Medical Inc. (T:TMD)

Business Focus: Advanced Medical Equipment & Technology (NEC)